<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/css" href="https://imcjms.com/assets/rss.css" ?><rss version="2.0">
<channel>
    <title>IMC Journal of Medical Science</title>
    <link>https://imcjms.com</link>
    <description>Ibrahim Medical College Journal of Medical Science</description>

                        <item>
                <title><![CDATA[Development of a Simple Prognostic Risk Score
for Patients with Bone Marrow Metastases from Solid Tumors: A Retrospective
Cohort Study]]></title>

                                    <author><![CDATA[Savas Gokcek MD*]]></author>
                                    <author><![CDATA[Mehmet Uzun, MD]]></author>
                                    <author><![CDATA[Mehmet Can Ugur, MD]]></author>
                                    <author><![CDATA[Beril Betul Cam MD]]></author>
                
                <link data-url="https://imcjms.com/registration/journal_full_text/626">
    https://imcjms.com/registration/journal_full_text/626
</link>
                <pubDate>Sat, 21 Nov 2026 11:50:15 +0000</pubDate>
                <category><![CDATA[Original Article]]></category>
                <comments><![CDATA[July 2026; Vol. 20(2):007]]></comments>
                <description>Abstract
Background and
objectives: Bone marrow metastasis (BMM) is a rare
complication of solid tumors that carries a dismal prognosis. Readily
applicable prognostic models for predicting survival in patients with BMM
remain limited. This study aimed to identify prognostic factors affecting
overall survival in solid tumor patients with BMM and to develop a clinically
applicable prognostic risk score.
Materials and
methods: Patients with solid tumors who developed
BMM during follow up were retrospectively evaluated. Demographic
characteristics, primary tumor features, metastatic disease status, hematologic
and biochemical parameters, performance status, and antitumor treatments
administered after BMM diagnosis were recorded. Overall survival (OS) was
defined as the time from the diagnosis of BMM to death or the last follow up.
Survival analyses were performed using the Kaplan–Meier method. Prognostic
factors were evaluated using Cox proportional hazards regression analyses. A
three tier prognostic risk score was established using the variables identified
as independent prognostic factors in the multivariable analysis.
Results: A total of
58 patients were included in the study. OS following the diagnosis of BMM was
notably poor. In multivariable analysis, de novo metastatic disease and the
lack of antitumor therapy following BMM diagnosis were independently associated
with inferior overall survival. Based on these two variables, the prognostic
risk score stratified patients into low- (0 risk factors), intermediate- (1
risk factor), and high risk (2 risk factors) groups. The median overall
survival was 7.8 months in the low risk group, 2.8 months in the intermediate
risk group, and 0.5 months in the high risk group. A significant difference in
OS was observed among the risk groups (log-rank p &amp;lt; 0.001).
Conclusion: In
patients with BMM originating from solid tumors, de novo metastatic disease and
the lack of antitumor therapy following BMM diagnosis were identified as
independent poor prognostic factors. A simple prognostic risk score based on
these two variables stratified patients into three distinct risk groups with
markedly different survival outcomes. External validation studies in larger,
independent cohorts are warranted to evaluate the model for clinical
implementation.
July
2026; Vol. 20(2):007. DOI: https://doi.org/10.55010/imcjms.20.016
*Correspondence: Savas Gokcek, Department of Medical Oncology, University of Health
Sciences, İzmir Tepecik Training and Research Hospital, Yenişehir, Konak,
35180, İzmir, Turkey Email:
©
2026 The Author(s). This is an open access article distributed under the terms
of the Creative
Commons Attribution License(CC BY 4.0)
&amp;nbsp;
&amp;nbsp;
Introduction
Bone
marrow metastasis (BMM) represents an infrequent but severe clinical entity
characterized by the dissemination of non hematological malignancies into the
bone marrow compartment, signifying advanced disease. Infiltration of the
hematopoietic niche by solid tumor cells frequently induces hematological
abnormalities, including anemia, thrombocytopenia, leukoerythroblastosis, and,
in severe instances, coagulation disorders and microangiopathic hemolytic
anemia. Hence, BMM should be kept in mind especially when encountering
unexplained cytopenias, a leukoerythroblastic blood profile, or features of
microangiopathic hemolytic anemia [1,2]. Moreover, bone marrow evaluation has
been documented to serve a vital role in identifying occult primary
malignancies [3].
While
symptomatic BMM from solid tumors remains an uncommon presentation, it
typically portends an unfavorable outcome. Earlier reports have demonstrated
that median overall survival (OS) among patients harboring BMM spans merely
from a few weeks to several months. Hung and colleagues identified a median OS
of 49 days in a cohort of 83 patients, where favorable performance status,
prostate cancer, platelet counts exceeding 50,000/µL, and receipt of antitumor
therapy correlated with prolonged survival [4]. In another series of 58
patients, Kucukzeybek et al. documented a median OS of 28 days post-BMM
diagnosis [5]. However, survival outcomes differ markedly across primary tumor
origins, with marrow involvement conferring a particularly grave prognosis in
malignancies such as gastric cancer [6].
The
clinical course of BMM exhibits marked heterogeneity depending on the primary
tumor type and the patient&#039;s general performance status. In a study evaluating
patients with breast cancer harboring bone marrow involvement, anemia and
thrombocytopenia were reported as the most frequent hematological
manifestations, with cytopenias improving following systemic therapy in a
substantial proportion of patients [7]. Similarly, in a more recent series
comprising diverse solid tumors, patients who received antitumor therapy
achieved a significantly longer median OS compared with those who did not (11.5
vs. 3.3 months; p &amp;lt; 0.01) [8]. These findings suggest that the diagnosis of
BMM alone does not entirely dictate patient prognosis, and that treatment
feasibility alongside clinical disease characteristics may play pivotal roles
in determining survival.
Identifying
prognostic factors in patients with BMM is crucial not only for estimating
expected survival outcomes but also for individualizing therapeutic decision
making. However, a significant proportion of available studies are limited by
small sample sizes, single center designs, and cohorts restricted to specific
primary tumor types. This limitation hampers the identification of shared
prognostic determinants in patients with BMM arising from diverse solid tumors
[1,4,5]. Furthermore, heterogeneous findings exist regarding the clinical
utility of routine hematological and biochemical parameters in establishing the
diagnosis of BMM and in risk assessment [2,3].
A
notable contribution in this field is the prognostic scoring study by Chou et
al., which encompassed 321 patients with BMM secondary to solid tumors. The
Marrow Metastases Prognostic Score (MMPS), developed in a derivation cohort of
165 patients and validated in an independent cohort of 156 patients,
incorporated Eastern Cooperative Oncology Group performance status (ECOG PS),
primary tumor site, platelet count, and the neutrophil to lymphocyte ratio
(NLR). This scoring system stratified patients into favorable, intermediate,
and poor prognostic groups, demonstrating significant survival discrimination
across both cohorts [9]. This study holds particular importance in illustrating
that clinical and laboratory variables can be effectively integrated into a
straightforward prognostic model for patients with BMM. Nevertheless, exploring
alternative risk stratification tools based on fewer variables that can be
readily implemented in routine clinical practice remains of clinical interest.
Therefore,
identifying independent clinical and laboratory determinants associated with OS
in patients with BMM arising from diverse solid tumors, and integrating these
factors into a straightforward prognostic model, represents a clinically meaningful
strategy. The objective of the present study was to delineate the independent
prognostic factors associated with OS in solid tumor patients who developed
BMM, and to construct a simple, clinically feasible prognostic risk score
capable of stratifying these patients into distinct risk categories based on
their survival outcomes.
&amp;nbsp;
Materials and methods
This study was designed as a retrospective cohort study
to evaluate the clinical characteristics and prognostic factors associated with
OS in patients diagnosed with BMM originating from solid tumors. Patients who
presented to the Hematology Outpatient Clinic of Izmir Tepecik Training and
Research Hospital between 2015 and 2025, with histopathologically confirmed BMM
and accessible clinical, laboratory, and survival data at the time of
diagnosis, were included in the study. The study population comprised a total
of 58 patients. The diagnosis of BMM was established based on the demonstration
of metastatic malignant cells in bone marrow aspiration and/or biopsy
specimens. All bone marrow aspiration and trephine biopsy procedures were
performed from the posterior superior iliac spine (PSIS) under local anesthesia
according to standard hematological protocols. Data regarding demographic
characteristics, primary tumor type, stage of disease, pattern of bone marrow
involvement, concomitant metastatic sites, ECOG, hematological and biochemical
laboratory parameters, and antitumor treatments administered following BMM
diagnosis were retrospectively recorded. The study was conducted in accordance
with the ethical principles outlined in the Declaration of Helsinki. The study
protocol was reviewed and approved by the Non-Interventional Research Ethics
Committee of the University of Health Sciences, İzmir Tepecik Training and
Research Hospital (Decision No: 2025/12-08, Date: January 5, 2026). Due to the
retrospective nature of the study, the requirement for informed consent was
waived by the ethics committee. Demographic and baseline clinical characteristics
comprised age, gender, ECOG, primary tumor histology, timing of metastasis,
marrow infiltration pattern, and concurrent distant metastatic burden.
Metastatic status was categorized into de novo metastatic disease versus
metachronous/recurrent metastasis arising during clinical follow up. The
infiltration pattern in the bone marrow was documented as either focal or
diffuse.Laboratory evaluation included hemoglobin, platelet count, absolute
neutrophil count, absolute lymphocyte count, absolute monocyte count, red cell
distribution width (RDW), C-reactive protein (CRP), albumin, lactate
dehydrogenase (LDH), and alkaline phosphatase (ALP) levels. In addition, the
NLR, platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR),
and CRP to albumin ratio (CAR) were calculated as systemic inflammatory and
immune response markers. All laboratory parameters were determined based on
values obtained closest to the time of BMM diagnosis.The study&#039;s primary
outcome was OS, calculated in months from BMM confirmation to death or the last
documented visit. Surviving patients were censored at their last known follow
up date. Patients presenting with locally advanced disease devoid of subsequent
distant metastatic recurrence were excluded from comparative analyses between
de novo versus metachronous metastatic cohorts.Statistical analyses were
conducted using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp.,
Armonk, NY, USA). The distribution characteristics of continuous variables were
evaluated based on skewness and kurtosis coefficients. Variables with both
coefficients within the &amp;nbsp;threshold were reported as mean &amp;nbsp;standard deviation, whereas variables with at
least one coefficient exceeding these limits were presented as median
(minimum–maximum). Categorical variables were expressed as frequencies and
percentages [n (%)]. Kaplan–Meier curves were generated to evaluate OS, and
between group comparisons were performed via the log-rank test. Median OS with
95% confidence intervals (CIs) was calculated according to the
Brookmeyer–Crowley methodology. Univariable Cox proportional hazards regression
analysis was initially performed to determine prognostic factors associated
with OS. Continuous laboratory parameters and inflammatory ratios were
dichotomized using their respective cohort median values. For albumin, the
established cutoff of 3.5 g/dL was applied based on the literature. Variables
demonstrating an association at a significance level of p &amp;lt; 0.20 in the
univariable analysis were incorporated into the multivariable Cox regression
model. Tumor type was entered into the model as a categorical variable retaining
all of its categories. Results were reported as hazard ratios (HRs), adjusted
hazard ratios (aHRs), and 95% CIs. Potential collinearity among covariates was
evaluated during the construction of the multivariable model. Because platelet
count and the PLR share the same hematological parameter, the risk of
multicollinearity arising from their concurrent inclusion was considered.
Consequently, platelet count was excluded from the multivariable model, whereas
the PLR was retained. A two-sided p-value &amp;lt; 0.05 was considered
statistically significant.
&amp;nbsp;
Development of the Prognostic Risk
Score
The
prognostic risk score was constructed based on variables that retained
independent prognostic significance for OS in the multivariable Cox regression
analysis. Accordingly, two adverse prognostic factors were identified: absence
of antitumor therapy following BMM diagnosis and de novo metastatic
presentation. Each adverse factor was assigned a score of 1, yielding a total
score ranging from 0 to 2 points. Patients were stratified into three risk
tiers based on their cumulative scores: low risk (0 points), intermediate risk
(1 point), and high risk (2 points). Prognostic discrimination across the
stratified risk categories was evaluated via Kaplan–Meier curves and compared
using the log-rank test. The clinical validity of the scoring model in relation
to OS was established by analyzing median survival estimates and the visual
separation of survival trajectories.
&amp;nbsp;
Results
Fiftyeight
patients were enrolled. The cohort had a mean age of 59.4 ± 14.7 years (range,
17–88 years), comprising 30 males (51.7%) and 28 females (48.3%). An ECOG PS of
0–1 was documented in 43 patients (74.1%), while 15 (25.9%) exhibited an ECOG
PS 2. The predominant
primary tumor histologies included breast cancer (34.5%), prostate cancer
(19.0%), and neuroendocrine carcinoma (15.5%) [specifically, the primary
locations were:
Gastroenteropancreatic
tract (GEP-NEC) (n = 5; including pancreas and gastric),
Bronchopulmonary
/ lung neuroendocrine carcinoma (n = 3), Unknown primary neuroendocrine carcinoma
(n = 1) ]. Fortythree patients (74.1%) presented with de novo metastatic BMM,
whereas 13 (22.4%) had initially locally advanced disease with subsequent
metastatic progression during followup (Table 1).
In
our cohort of 58 patients: 38 patients (65.5%) received diseasedirected
antitumor therapy (palliative systemic chemotherapy, targeted therapy, or
endocrine therapy) after the diagnosis of BMM. 20 patients (34.5%) did not
receive antitumor therapy and were managed exclusively with best supportive
care due to poor performance status, rapid disease deterioration, or profound
cytopenias.
BMM
exhibited a diffuse pattern in 57 patients (98.3%) and a focal pattern in 1
patient (1.7%). Among concomitant metastatic sites, distant lymph node
metastasis (44.8%) and liver metastasis (37.9%) were the most prevalent.
Peritoneal and lung metastases were identified in 13.8% and 6.9% of patients,
respectively (Table 1).
&amp;nbsp;
Table-1: Sociodemographic and Clinical
Characteristics of the Patients
&amp;nbsp;
&amp;nbsp;
At
the time of BMM diagnosis, the mean hemoglobin level was 8.9 ± 2.2 g/dL. The
median neutrophil and lymphocyte counts were 4,200/µL and 1,700/µL,
respectively. The mean albumin level was 3.6 ± 0.5 g/dL, whereas the median
CRP, LDH, and ALP levels were 33.0 mg/L, 434 U/L, and 229 U/L, respectively.
The
median values of the inflammatory/prognostic ratios were 2.3 for NLR, 64.8 for
PLR, 3.0 for LMR, and 9.4 for CAR (Table 2).
&amp;nbsp;
Table-2: Hematologic and Biochemical Parameters and
Inflammatory Ratios of the Patients
&amp;nbsp;
&amp;nbsp;
Univariate
Cox regression analysis was performed to determine prognostic factors for OS.
Male sex (HR, 1.796; 95% CI, 1.039–3.105; p=0.036), ECOG performance status ≥2
(HR, 6.892; 95% CI, 3.337–14.235; p&amp;lt;0.001), NLR above the median value (HR,
1.814; 95% CI, 1.025–3.213; p=0.041), and high ALP level (HR, 1.773; 95% CI,
1.019–3.086; p=0.043) were associated with a higher risk of death (Table 3).
Conversely,
receiving antitumor therapy after the diagnosis of BMM was significantly
associated with a lower risk of death (HR, 0.125; 95% CI, 0.056–0.280;
p&amp;lt;0.001). De novo metastatic disease demonstrated a borderline significant
association with a higher risk of death (HR, 1.820; 95% CI, 0.991–3.345;
p=0.054).
In
contrast, RDW above the median value was associated with a lower risk of death
in this cohort (HR, 0.444; 95% CI, 0.249–0.794; p=0.006). Tumor type was also
significantly associated with overall survival (p&amp;lt;0.001); neuroendocrine
carcinoma was associated with a markedly higher risk of death compared to
breast cancer (HR, 10.288; 95% CI, 3.907–27.086; p&amp;lt;0.001). Detailed results
for the remaining variables are presented in Table 3.
The
pattern of bone marrow involvement was not significantly associated with
survival. As focal involvement was observed in only one patient, the confidence
interval for this comparison was wide, and the result was considered
descriptive (HR, 2.595; 95% CI, 0.346–19.448; p=0.354) (Table 3).
&amp;nbsp;
Table-3: Results of Univariate Cox Regression Analysis
for Overall Survival
&amp;nbsp;
&amp;nbsp;
Variables
demonstrating an association at the p &amp;lt; 0.20 level in the univariate
analysis were included in the multivariable Cox regression model. To minimize
potential collinearity, platelet count was excluded from the model and PLR was
retained, as both share the same hematologic parameter.
In
the multivariable analysis, two variables remained independent prognostic
factors for OS. Receiving antitumor therapy following the diagnosis of BMM was
associated with a lower risk of death (adjusted HR, 0.070; 95% CI, 0.015–0.324;
p&amp;lt;0.001). Conversely, de novo metastatic disease was independently
associated with an increased risk of death (adjusted HR, 2.329; 95% CI,
1.161–4.673; p=0.017) (Table 4; Figure 1).
Elevated
NLR, which was found to be significant in the univariate analysis, did not reach
statistical significance in the multivariable analysis (adjusted HR, 2.275; 95%
CI, 0.951–5.443; p=0.065). Similarly, neuroendocrine carcinoma histology was
not confirmed as an independent prognostic factor in the multivariable model
(adjusted HR, 2.828; 95% CI, 0.815–9.813; p=0.101). Other clinical and
laboratory variables were also not statistically significant in the
multivariable model (Table 4).
The
multivariable model was statistically significant overall (likelihood ratio , df = 15, p &amp;lt; 0.001)
(Figure 1).
&amp;nbsp;
Table-4: Results of Multivariable Cox Regression
Analysis for OS
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
Development of the Prognostic Risk
Score
A
simple prognostic risk score was constructed using the two variables identified
as independent prognostic factors in the multivariable Cox regression analysis.
De novo metastatic disease and the absence of antitumor therapy following the
diagnosis of BMM were defined as adverse prognostic factors, with 1 point
assigned to each factor. Consequently, the total score ranged from 0 to 2.
Based on their scores, patients were stratified into three risk groups: low
risk (0 points), intermediate risk (1 point), and high risk (2 points) (Table
5).
&amp;nbsp;
Table-5: Comparison of OS by Prognostic Risk Group
&amp;nbsp;
&amp;nbsp;
In
the low risk group (n = 14), median OS was 7.8 months (95% CI, 1.7–25.5),
compared with 2.8 months (95% CI, 1.6–5.5) in the intermediate risk group (n =
36) and only 0.5 months (95% CI, 0.3–1.0) in the high risk group (n = 7) (Table
5).
A
distinct and highly statistically significant difference in OS was observed
among the risk groups (log-rank &amp;nbsp;= 63.14, df = 2, p &amp;lt; 0.001). Kaplan–Meier
analysis demonstrated a clear separation of the survival curves across the risk
groups (Figure 2). Furthermore, the stepwise decline in median OS from 7.8 to
2.8 months and subsequently to 0.5 months with increasing risk score
demonstrated a strong gradient relationship between the score and survival
outcomes (Table 5; Figure 2).
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
Discussion
In
this retrospective study, we identified two independent factors associated with
OS in patients with BMM from solid tumors: de novo metastatic disease and the
lack of antitumor therapy following BMM diagnosis. A simple prognostic risk
score derived from these two variables stratified patients into three distinct
groups: low, intermediate, and high risk. Median OS decreased stepwise from 7.8
months in patients with no risk factors to 2.8 months in those with one risk
factor, and down to 0.5 months in those with two risk factors (log-rank p &amp;lt;
0.001). These findings suggest that, despite the heterogeneous nature of
primary tumors associated with BMM, a limited number of readily available
clinical variables can provide clinically meaningful prognostic discrimination.
BMM
is an infrequent yet particularly aggressive manifestation of advanced solid
malignancies. Although previous studies have documented markedly dismal
survival outcomes following the diagnosis of BMM, prognosis has been shown to
vary substantially depending on primary tumor type, performance status,
hematologic derangements, and the feasibility of administering antitumor
therapy [4,5]. The biological and clinical complexity of BMM has also been
highlighted in recent comprehensive reviews, which detail the reciprocal
interactions between circulating tumor cells and the bone marrow
microenvironment, as well as the profound hematologic consequences of diffuse
marrow infiltration [10].
In
our study, de novo metastatic disease was independently associated with worse
OS. Patients presenting with metastatic disease at the time of initial cancer
diagnosis had more than a two fold increased risk of death compared to those
who developed metachronous metastases. Although the underlying biological
mechanism cannot be definitively established due to the retrospective design, de
novo metastatic presentation may reflect a more aggressive tumor biology, a
higher initial disease burden, or early hematogenous dissemination. In
particular, the timing and pattern of metastatic spread may provide prognostic
insights extending beyond the mere anatomical presence of BMM.
The
second independent prognostic factor identified in our study was the
administration of antitumor therapy following the diagnosis of BMM. Patients
who received antitumor therapy exhibited significantly longer survival compared
to those who did not. This finding is consistent with a recent study evaluating
solid tumor patients with BMM, which reported a median OS of 11.5 months in
patients receiving antitumor therapy versus 3.3 months in untreated patients
[11]. Similarly, the association between active treatment and prolonged
survival has been demonstrated in other BMM cohorts, suggesting that carefully
selected patients with an adequate clinical performance status may derive
meaningful benefit from disease directed therapy.
More
recent data also corroborate the prognostic relevance of treatment feasibility.
In a retrospective study evaluating 41 solid tumor patients with bone marrow
involvement, although the median OS for the entire cohort was merely 23 days,
patients receiving antitumor therapy had a significantly longer median survival
than those managed with supportive care alone (158 vs. 13 days; p &amp;lt; 0.001)
[12]. These findings are broadly consistent with our results and support the
notion that the ability to tolerate active treatment serves as a critical
determinant of clinical outcomes in patients with BMM.
However,
the association between treatment and survival must be interpreted with
caution. The decision to initiate therapy following a BMM diagnosis is not
randomized; rather, it is heavily influenced by performance status, organ
function, hematologic reserve, disease burden, symptomatology, and the
clinician&#039;s overall clinical judgment. Treatment status may therefore reflect
patient fitness and baseline eligibility rather than solely the therapeutic
efficacy of antitumor agents. Furthermore, an earlier study of 30 patients with
BMM reported significantly prolonged survival in those who received systemic
therapy compared with those receiving supportive care alone, underscoring the
strong interplay between treatment fitness and clinical outcomes [13].
The
prognostic role of systemic inflammation was also evaluated in our study.
Although the NLR was associated with OS in the univariate analysis, it lost
independent significance following multivariable analysis. This finding should
not be interpreted as an absence of prognostic relevance for NLR in cancer. In
an umbrella review evaluating systematic reviews and meta analyses, elevated
NLR was consistently associated with poorer outcomes across numerous
malignancies, though the strength of this association varied according to tumor
type and clinical setting [14]. In our cohort, the loss of significance after
multivariable adjustment may be attributable to the limited sample size, the
heterogeneity of primary tumors, and the collinear overlap of inflammatory
parameters with other indicators of disease severity.
Similarly,
various laboratory variables—including ALP, LDH, and RDW—were associated with
survival in univariate analyses but failed to retain independent prognostic
significance in the final model. This may be related to the unique biological
characteristics of BMM. In this setting, hematologic and biochemical
derangements often arise from multiple convergent processes, such as marrow
infiltration, systemic inflammation, high tumor burden, organ dysfunction, and
widespread metastatic dissemination. Consequently, while individual laboratory
parameters harbor prognostic value, their independent contributions may become
less pronounced when major clinical variables are evaluated concurrently.
A
notable finding of our study is the development of a simple, two factor
prognostic risk score. The previously established and independently validated
Marrow Metastases Prognostic Score (MMPS) incorporates ECOG performance status,
primary tumor site, platelet count, and NLR [9]. The MMPS successfully
stratified patients into good, intermediate, and poor prognostic groups with
distinctly divergent median survivals in both the development and validation
cohorts. In contrast to the MMPS, our model relies on only two readily
accessible clinical variables: de novo metastatic presentation and the omission
of antitumor therapy following BMM diagnosis. Consequently, the present model
should be viewed not as a replacement for the MMPS, but rather as a simplified
alternative approach.
The
primary clinical appeal of our score lies in its simplicity. One point is
assigned to each adverse factor, yielding a total score ranging from 0 to 2. In
our cohort, this straightforward classification established a distinct survival
gradient, with median OS dropping from 7.8 months in the low risk group to 2.8
months in the intermediate risk group, and to just 0.5 months in the high risk
group. Such an easily applicable stratification tool may prove particularly
useful in routine clinical practice, where rapid decision making regarding
treatment intensity, supportive and palliative care allocation, and prognostic
communication is essential.
Nevertheless,
the proposed score should be considered exploratory. This study was conducted
in a relatively small cohort, and the model was both developed and evaluated
within the same patient population. Consequently, the observed discrimination
among risk groups may overestimate its predictive performance in independent
cohorts. Current guidelines for prognostic prediction models emphasize
transparent reporting across model development, variable selection, outcome
definition, predictive performance, and validation processes [15]. Therefore,
external validation in independent cohorts is mandatory before this risk score
can be adopted into routine clinical practice.
The
relatively small sample size of our study represents another notable
limitation. Although the final risk score comprises only two variables, the
initial multivariable Cox model included a relatively large number of candidate
parameters compared to the number of patients and observed events.
Methodological principles in prognostic modeling emphasize that adequate sample
size must be evaluated not merely by total patient count, but critically in
relation to the number of events and candidate predictors evaluated; an
insufficient event to variable ratio can lead to model overfitting and unstable
risk estimates [16]. Consequently, the current scoring system should be
regarded as a preliminary prognostic framework that warrants validation in
larger multicenter cohorts.
A
particularly critical methodological issue is the inclusion of antitumor
therapy administered after BMM diagnosis as one of the two components of the
risk score. Because treatment is initiated following the diagnosis of BMM and
may occur at varying time points during followup, patients classified as having
received therapy inherently had to survive long enough to receive it.
Overlooking the time-dependent nature of treatment exposure can introduce
immortaltime bias, thereby potentially inflating the apparent survival
advantage attributed to antitumor therapy [17].
This
issue is particularly relevant to the strong association between treatment
receipt and survival observed in our study. Consequently, the present analysis
should not be interpreted as establishing a causal treatment effect. Instead,
receiving therapy likely reflects both therapeutic exposure and the patient&#039;s
baseline clinical fitness to tolerate intervention. In observational studies,
patients who survive longer naturally have greater opportunities to receive
therapy, whereas those who succumb early are invariably categorized as
untreated, introducing survivor treatment bias [18]. To mitigate this
limitation, future studies should model treatment exposure as a time dependent
covariate or implement an appropriate landmark analysis.
Our
study has several additional limitations. First, its retrospective design
inherently carries the potential for selection and information bias. Second,
the inclusion of diverse primary tumor histologies within a single cohort may
have contributed to outcome heterogeneity due to inherent differences in tumor
biology and treatment responsiveness. Third, the relatively modest sample size
limited the statistical precision of subgroup analyses. Fourth, the proposed
prognostic score has not yet undergone external validation. Fifth, from a
diagnostic perspective, bone marrow aspiration alone may yield non-diagnostic
or hemodiluted samples (&#039;dry tap&#039;) in the presence of extensive marrow
necrosis, desmoplasia, or dense tumor cell packing. The concurrent performance
of a trephine core biopsy with immunohistochemical staining remains crucial to
enhance diagnostic yield, prevent false-negative aspirates, and accurately
evaluate the extent of marrow infiltration by solid malignancies. These
limitations are particularly pertinent given the substantial biological and
clinical heterogeneity of patients with BMM arising from distinct primary
malignancies.
Nevertheless,
our study has several clinically important strengths. BMM is an uncommon
clinical entity, and most available literature is derived from relatively small
retrospective cohorts. Rather than merely describing the clinical
characteristics of BMM, our study specifically focused on prognostic risk
stratification. More importantly, the proposed score relies on readily
accessible clinical variables that do not require specialized molecular testing
or complex computational algorithms. The distinct survival separation observed
across the three risk categories supports the further investigation of this
pragmatic approach in future studies.
Future
multicenter studies should validate the proposed score in larger and more
diverse patient populations. Ideally, such investigations should directly
compare its prognostic performance against the previously established MMPS,
evaluate both discrimination and calibration metrics, and account for the
time-dependent nature of treatment exposure. Upon successful external
validation, this simple two-factor score could complement existing prognostic
tools and assist clinicians in identifying patients with particularly limited
life expectancy following a diagnosis of BMM.
&amp;nbsp;
Conclusion
In
summary, our study demonstrates that de novo metastatic presentation and the
omission of antitumor therapy following the diagnosis of BMM are independently
associated with poor overall survival in patients with solid tumor related BMM.
A simple, two factor prognostic score based on these variables stratified
patients into low, intermediate, and high risk categories with markedly
distinct survival outcomes. The simplicity of this model and its reliance on
readily available clinical variables may facilitate pragmatic prognostic
assessment in this rare and clinically challenging patient population.
Nonetheless, given the retrospective design, small sample size, potential
treatment related immortal time bias, heterogeneity of primary tumors, and lack
of external validation, this score should currently be considered exploratory
and hypothesis generating. Larger multicenter studies are warranted to validate
its prognostic utility.
&amp;nbsp;
Conflict of interest
The
authors declare that they have no competing interests, either financial or
non-financial, related to the work presented in this manuscript.
&amp;nbsp;
Funding
This
research received no specific grant from any funding agency in the public,
commercial, or not-for-profit sectors.
&amp;nbsp;
Authors’ Contributions
SG
conceptualized and designed the study, performed the statistical analyses, and
drafted the original manuscript. MU supervised the research, managed data
collection and curation, and critically revised the manuscript for important intellectual
content. MCU contributed to data acquisition, formal analysis, and
interpretation of clinical and pathological data. BBC assisted in data
collection, literature review, and manuscript preparation. All authors read and
approved the final version of the manuscript. 
&amp;nbsp;
References
1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Yang R, Jia L, Cui J. Mechanism and
clinical progression of solid tumors bone marrow metastasis. Front Pharmacol.
2024 May 6; 15: 1390361. doi:
10.3389/fphar.2024.1390361.
2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Zhang L, Chen F, Xu L, Li N, Zhuo Q, Guo Y,
et al. Comprehensive review of solid tumor bone marrow metastasis. Crit Rev
Oncol Hematol. 2024 Feb; 194: 104248.
doi: 10.1016/j.critrevonc.2023.104248.
3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Ozkalemkas F, Ali R, Ozkocaman V, Ozcelik
T, Ozan U, Ozturk H, et al. The bone marrow aspirate and biopsy in the
diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19
cases. BMC Cancer. 2005 Nov 1; 5:
144. doi: 10.1186/1471-2407-5-144.
4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Hung YS, Chou WC, Chen TD, Chen TC, Wang
PN, Chang H, ey al. Prognostic factors in adult patients with solid cancers and
bone marrow metastases. Asian Pac J Cancer Prev. 2014; 15(1): 61-7. doi:
10.7314/apjcp.2014.15.1.61.
5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Kucukzeybek BB, Calli AO, Kucukzeybek Y,
Bener S, Dere Y, Dirican A, Payzin KB, et al. The prognostic significance of
bone marrow metastases: evaluation of 58 cases. Indian J Pathol Microbiol.
2014 Jul-Sep; 57(3): 396-9. doi:
10.4103/0377-4929.138728.
6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Ekinci AŞ, Bal O, Ozatlı T, Türker I, Eşbah
O, Demirci A, et al. Gastric carcinoma with bone marrow metastasis: a case
series. J Gastric Cancer. 2014 Mar; 14(1):
54-7. doi: 10.5230/jgc.2014.14.1.54. Epub 2014 Mar 31.
7.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Kopp HG, Krauss K, Fehm T, Staebler A, Zahm
J, Vogel W, et al. Symptomatic bone marrow involvement in breast
cancer--clinical presentation, treatment, and prognosis: a single institution
review of 22 cases. Anticancer Res. 2011 Nov; 31(11): 4025-30.
8.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Yang H, He F, Yuan T, Xu W, Cao Z. Clinical
features and treatment of bone marrow metastasis. Oncol Lett. 2023 Jun
16; 26(2): 332. doi:
10.3892/ol.2023.13918.
9.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Chou WC, Yeh KY, Peng MT, Chen JS, Wang HM,
Lin YC, et al. Development and Validation of a Prognostic Score to Predict
Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases. Medicine
(Baltimore). 2015 Jun; 94(23): e966.
doi: 10.1097/MD.0000000000000966. Erratum in: Medicine (Baltimore). 2015
Jul; 94(26): 1. Li, Shau-Hsuan
[Added]. 
10.&amp;nbsp; Tyagi R, Singh A, Garg B, Sood N. Beware of
Bone Marrow: Incidental Detection and Primary Diagnosis of Solid Tumours in
Bone Marrow Aspiration and Biopsies; A Study of 22 Cases. Iran J Pathol.
2018 Winter; 13(1): 78-84.
11.&amp;nbsp; Rani HS, Hui M, Manasa PL, Uppin SG, Uppin MS,
Paul TR, et al. Bone Marrow Metastasis of Solid Tumors: A Study of 174 Cases
Over 2 Decades from a Single Institution in India. Indian J Hematol Blood
Transfus. 2022 Jan; 38(1): 8-14.
doi: 10.1007/s12288-021-01418-9.
12.&amp;nbsp; Zhang B, Jin L, Wu D, Xu J, Guo S, Li J, et
al. Bone marrow involvement in solid tumors - a retrospective observational
study. Front Oncol. 2025 Sep 8; 14:
1434709. doi: 10.3389/fonc.2024.1434709.
13.&amp;nbsp; Zhou MH, Wang ZH, Zhou HW, Liu M, Gu YJ, Sun
JZ. Clinical outcome of 30 patients with bone marrow metastases. J Cancer
Res Ther. 2018 Jun; 14(Supplement):
S512-S515. doi: 10.4103/0973-1482.172717. 
14.&amp;nbsp; Cupp MA, Cariolou M, Tzoulaki I, Aune D,
Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer
prognosis: an umbrella review of systematic reviews and meta-analyses of
observational studies. BMC Med. 2020 Nov 20; 18(1): 360. doi: 10.1186/s12916-020-01817-1.
15.&amp;nbsp; Collins GS, Reitsma JB, Altman DG, Moons KG.
Transparent Reporting of a multivariable prediction model for Individual
Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med.
2015 Jan 6; 162(1): 55-63. doi:
10.7326/M14-0697. Erratum in: Ann Intern Med. 2015 Apr 21; 162(8): 600. doi: 10.7326/L15-0078-4.
16.&amp;nbsp; Riley RD, Snell KI, Ensor J, Burke DL, Harrell
FE Jr, Moons KG, et al. Minimum sample size for developing a multivariable
prediction model: PART II - binary and time-to-event outcomes. Stat Med.
2019 Mar 30; 38(7): 1276-1296. doi:
10.1002/sim.7992. Epub 2018 Oct 24. Erratum in: Stat Med. 2019 Dec 30; 38(30): 5672. doi: 10.1002/sim.8409.
17.&amp;nbsp; Jones M, Fowler R. Immortal time bias in
observational studies of time-to-event outcomes. J Crit Care. 2016 Dec; 36: 195-199. doi:
10.1016/j.jcrc.2016.07.017.
18.&amp;nbsp; Austin PC, Mamdani MM, van Walraven C, Tu JV.
Quantifying the impact of survivor treatment bias in observational studies. J
Eval Clin Pract. 2006 Dec; 12(6):
601-12. doi: 10.1111/j.1365-2753.2005.00624.x.
&amp;nbsp;
&amp;nbsp;
Cite this article
as:
Gokcek
S,Uzun M,Ugur MC,Cam BB.Development of a
Simple Prognostic Risk Score for Patients with Bone Marrow Metastases from
Solid Tumors: A Retrospective Cohort Study. IMC J Med Sci. 2026; 20(2):006. DOI:https://doi.org/10.55010/imcjms.20.015</description>

            </item>
            
    <copyright>2026 Ibrahim Medical College. All rights reserved.</copyright>
</channel>
</rss>
